ARDXArdelyxARDX info
$6.15info-1.13%24h
Global rank6367
Market cap$1.43B
Change 7d-2.23%
YTD Performance0.16%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Ardelyx (ARDX) Stock Overview

    Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

    ARDX Stock Information

    Symbol
    ARDX
    Address
    400 Fifth AvenueWaltham, MA 02451United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.ardelyx.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    510 745 1700

    Ardelyx (ARDX) Price Chart

    -
    Value:-

    Ardelyx Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $6.15
    N/A
    Market Cap
    $1.43B
    N/A
    Shares Outstanding
    232.14M
    N/A
    Employees
    133.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org